Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra

Joint Bone Spine. 2013 Mar;80(2):206-7. doi: 10.1016/j.jbspin.2012.07.005. Epub 2012 Sep 19.

Abstract

Erdheim-Chester disease is a rare non-langerhans cell histiocytosis characterized by infiltration of foamy CD68-positive but CD1a-negative macrophages and fibro-inflammatory lesions as retroperitoneal, periureteral areas or bones. Interferon-α therapy has been used as treatment but it had variable efficiency and limited tolerance. More recently, a recombinant form of interleukin-1 receptor antagonist (anakinra) was used with success but no skeletal radiological improvement was recorded. We report here a case of interleukin-1 receptor antagonist in the treatment of refractory bones infiltration in Erdheim-Chester disease. After 1 year of treatment, the positron emission tomography-computed tomography showed an outstanding response of the skeletal involvement with clearly lower and smaller hypermetabolism images.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Erdheim-Chester Disease / diagnostic imaging*
  • Erdheim-Chester Disease / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Multimodal Imaging*
  • Positron-Emission Tomography*
  • Tomography, X-Ray Computed*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein